Fraga M, Forteza J
Department of Pathology, Clinical and Universitary Hospital, Santiago de Compostela, Spain.
Histol Histopathol. 2007 Aug;22(8):923-35. doi: 10.14670/HH-22.923.
The Hodgkin lymphoma (HL) is a B-cell lymphoma, as was proved by molecular studies with single-cell PCR. Histologically, it is characterized by a minority of neoplastic cells, Reed-Sternberg cells and its variants, related to a variable non-neoplastic inflammatory background. Nowadays, (WHO classification) the following types of HL are recognized: Nodular Paragranuloma and the Classical Hodgkin Lymphoma, the latter including Nodular Sclerosis, Mixed Cellularity, Lymphocyte-rich Classical Hodgkin Lymphoma and Lymphocyte Depletion. Morphology together with immunohistochemical studies allows to classify the different forms of Hodgkin lymphoma and to make a differential diagnosis with non-Hodgkin lymphomas. All classical Hodgkin lymphomas are treated similarly, and chances for remission and survival are currently good. Molecular parameters should be added to the current classification and patients could benefit from new therapeutic targets.
霍奇金淋巴瘤(HL)是一种B细胞淋巴瘤,单细胞PCR分子研究已证实这一点。在组织学上,其特征是少数肿瘤细胞,即里德-施特恩伯格细胞及其变体,伴有可变的非肿瘤性炎症背景。如今(世界卫生组织分类),公认的HL类型如下:结节性副肉芽肿和经典型霍奇金淋巴瘤,后者包括结节硬化型、混合细胞型、富于淋巴细胞的经典型霍奇金淋巴瘤和淋巴细胞消减型。形态学检查以及免疫组化研究有助于对霍奇金淋巴瘤的不同形式进行分类,并与非霍奇金淋巴瘤进行鉴别诊断。所有经典型霍奇金淋巴瘤的治疗方法相似,目前缓解和生存几率良好。分子参数应纳入当前分类,患者可能会受益于新的治疗靶点。